KEYNOTE—522 and male spindle cell carcinoma of the breast: A case report

Metaplastic Breast Cancer (MBC) is a rare group of tumors often presenting as triple-negative. MBC accounts for less than 1% of all breast cancers with the spindle cell variant comprising less than 0.5%. While rare, spindle cell carcinoma is the commonest subtype in the western world. It has a more...

Full description

Saved in:
Bibliographic Details
Published inRare tumors Vol. 15; p. 20363613231163730
Main Authors Niver, Harper E, Foxhall, Edward, Lahiry, Anup
Format Journal Article
LanguageEnglish
Published London, England SAGE Publications 01.03.2023
Sage Publications Ltd
SAGE Publishing
Subjects
Aggressive behavior
Breast cancer
Breast carcinoma
Carboplatin
Case Report
Case reports
Cyclophosphamide
Doxorubicin
Mens health
Paclitaxel
Pembrolizumab
Male breast cancer
Spindle Cell breast cancer
KEYNOTE 522
Metaplastic Breast Cancer
Online AccessGet full text

Cover

More Information
Summary:Metaplastic Breast Cancer (MBC) is a rare group of tumors often presenting as triple-negative. MBC accounts for less than 1% of all breast cancers with the spindle cell variant comprising less than 0.5%. While rare, spindle cell carcinoma is the commonest subtype in the western world. It has a more aggressive biological behavior with increased risk of recurrence and death due to disease compared to triple negative breast cancers. There is no treatment guideline for management of MBC due to the rarity of the disease. Instead, treatment is theorized based off success with other types of aggressive breast and metaplastic cancers of different tissue. We present the first known case report of male spindle cell carcinoma of the breast treated with KEYNOTE-522 regimen. Therapy included a first phase with pembrolizumab (dose of 200 mg) every 3 weeks plus paclitaxel and carboplatin and second phase, with four cycles of pembrolizumab with doxorubicin-cyclophosphamide.
ISSN:2036-3613
2036-3605
2036-3613
DOI:10.1177/20363613231163730